View of Epirubicin and Docetaxel as neoadjuvant treatment of hormone receptor positive, HER-2 negative breast cancer: results from two successive phase II studies

Return to Article Details Epirubicin and Docetaxel as neoadjuvant treatment of hormone receptor positive, HER-2 negative breast cancer: results from two successive phase II studies Download Download PDF